Pancreas cancer screening trial enrolls 9,000 High-Risk individuals
NCT ID NCT02000089
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This Phase 3 study is testing whether markers in pancreatic fluid and blood can detect early pancreas cancer in people with high genetic risk. Participants receive a secretin injection to collect fluid during an endoscopy. The goal is to improve early detection in those with hereditary pancreatitis, Peutz-Jeghers syndrome, strong family history, or certain gene mutations.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Secretin injection (ChiRhoStim) to collect pancreatic fluid for biomarker testing
What this could lead to
If successful, this could lead to a reliable screening method to catch pancreas cancer early in people with high genetic risk.
What could go wrong
This is a screening study, not a treatment. It may not prove that early detection improves survival, and false positives could cause unnecessary procedures.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PANCREAS CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Email: •••••@•••••
Locations
-
Case Comprehensive Cancer Center, Case Western Medical Reserve
RECRUITINGCleveland, Ohio, 44106, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Columbia University Medical Center
RECRUITINGNew York, New York, 10032, United States
Contact
Contact Email: •••••@•••••
-
Dana Farber Cancer Center, Harvard University
RECRUITINGBoston, Massachusetts, 02215, United States
Contact Email: •••••@•••••
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Johns Hopkins Hospital
RECRUITINGBaltimore, Maryland, 21287, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Contact
-
NYU Langone Medical Center
RECRUITINGNew York, New York, 10016, United States
Contact Email: •••••@•••••
Contact
-
University of Michigan
RECRUITINGAnn Arbor, Michigan, 48109, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
University of Pennsylvania
RECRUITINGPhiladelphia, Pennsylvania, 19104, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Email: •••••@•••••
-
University of Pittsburgh
RECRUITINGPittsburgh, Pennsylvania, 15213, United States
Contact Email: •••••@•••••
Contact
Contact Email: •••••@•••••
-
Yale University
RECRUITINGNew Haven, Connecticut, 06520, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••